Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsSteven Aronin, MD, FACP
Associate Clinical ProfessorAbout
Research
Publications
2025
Sulopenem versus Amoxicillin/Clavulanate for the Treatment of Uncomplicated Urinary Tract Infection.
Puttagunta S, Aronin S, Gupta J, Das A, Gupta K, Dunne M. Sulopenem versus Amoxicillin/Clavulanate for the Treatment of Uncomplicated Urinary Tract Infection. NEJM Evidence 2025, 4: evidoa2400414. PMID: 40552968, DOI: 10.1056/evidoa2400414.Peer-Reviewed Original ResearchConceptsUrinary tract infectionUncomplicated urinary tract infectionsIntent-to-treat populationSusceptible to amoxicillin/clavulanateTract infectionsUrine cultureAdverse eventsTreatment of uncomplicated urinary tract infectionsCombined population of patientsPatients treated with amoxicillin/clavulanateTreatment-emergent adverse eventsBaseline urine culturePositive urine cultureMild adverse eventsPopulation of patientsTreatment of adult womenClasses of antibioticsMicrobiological eradicationBaseline pathogensClinical cureDouble-blindMedian ageTrial medicationAmoxicillin/clavulanateAntimicrobial resistanceIn vitro activity of sulopenem and comparator agents against US Enterobacterales clinical isolates collected during the SENTRY antimicrobial surveillance program in 2023
Aronin S, Huband M, Becker H, Fedler K, Dunne M. In vitro activity of sulopenem and comparator agents against US Enterobacterales clinical isolates collected during the SENTRY antimicrobial surveillance program in 2023. Journal Of Global Antimicrobial Resistance 2025, 44: 152-159. PMID: 40555323, DOI: 10.1016/j.jgar.2025.06.013.Peer-Reviewed Original ResearchEnterobacterales clinical isolatesUrinary tract infectionIn vitro activityClinical isolatesEnterobacterales isolatesTract infectionsComparator agentsCLSI broth microdilution reference methodBroth microdilution reference methodSENTRY Antimicrobial Surveillance ProgramTreat urinary tract infectionsResistance phenotypeIsolates non-susceptibleMicrodilution reference methodAntimicrobial Surveillance ProgramOral antimicrobial agentsUS medical centersTreatment of womenUrinary isolatesInfection typeNon-susceptibilityOral formulationClinical evaluationUS FDABacterial infectionsCharacterization of sulopenem antimicrobial activity using in vitro time-kill kinetics, synergy, post-antibiotic effect, and sub-inhibitory MIC effect methods against Escherichia coli and Klebsiella pneumoniae isolates
Maher J, Huband M, Lindley J, Rhomberg P, Aronin S, Puttagunta S, Castanheira M. Characterization of sulopenem antimicrobial activity using in vitro time-kill kinetics, synergy, post-antibiotic effect, and sub-inhibitory MIC effect methods against Escherichia coli and Klebsiella pneumoniae isolates. Microbiology Spectrum 2025, 13: e01898-24. PMID: 39907459, PMCID: PMC11878024, DOI: 10.1128/spectrum.01898-24.Peer-Reviewed Original ResearchConceptsUncomplicated urinary tract infectionsPost-antibiotic effectIntra-abdominal infectionsTreatment of urinary tractTime-kill testsMultidrug-resistant pathogensBaseline MICPenem antibioticUrinary tractPAE effectsClinical developmentBroth microdilution susceptibility testingPhase 3 clinical trialsKlebsiella pneumoniae isolatesOral dosing regimenUrinary tract infectionMicrodilution susceptibility testingPAE-SMETime-kill assayTime-kill kineticsStudy evaluated inMg/500 mgAmoxicillin-clavulanateTract infectionsSusceptibility testingP-1574. Asymptomatic Bacteriuria Not a Predictor of Clinical Failure in Uncomplicated Urinary Tract Infections (uUTI): A Prospective Analysis of Women Treated for uUTI from the REASSURE Trial
Aronin S, Dunne M, Puttagunta S. P-1574. Asymptomatic Bacteriuria Not a Predictor of Clinical Failure in Uncomplicated Urinary Tract Infections (uUTI): A Prospective Analysis of Women Treated for uUTI from the REASSURE Trial. Open Forum Infectious Diseases 2025, 12: ofae631.1741. PMCID: PMC11776810, DOI: 10.1093/ofid/ofae631.1741.Peer-Reviewed Original ResearchPresence of asymptomatic bacteriuriaAsymptomatic bacteriuriaUncomplicated UTIClinical failureMMITT populationTOC visitClinical responseEfficacy endpointTreatment armsTreatment of uncomplicated UTIUncomplicated urinary tract infectionsPredictor of clinical failureTreatment of UTIUrinary tract infectionAdult womenAnalysis of womenCausative uropathogensDouble-dummyActive controlled trialUTI symptomsDouble-blindAsymptomatic patientsPrimary endpointTract infectionsEfficacy outcomesP-1107. Oral Sulopenem/probenecid for Uncomplicated Urinary Tract Infections (uUTI): Results from the REASSURE Trial
Puttagunta S, Aronin S, Gupta J, Das A, Gupta K, Dunne M. P-1107. Oral Sulopenem/probenecid for Uncomplicated Urinary Tract Infections (uUTI): Results from the REASSURE Trial. Open Forum Infectious Diseases 2025, 12: ofae631.1295. PMCID: PMC11777793, DOI: 10.1093/ofid/ofae631.1295.Peer-Reviewed Original ResearchUncomplicated urinary tract infectionsTreatment-emergent adverse eventsTreatment of uncomplicated urinary tract infectionsSusceptible to amoxicillin/clavulanateMMITT populationAdverse eventsFrequent treatment-emergent adverse eventsTreatment of multidrug-resistant infectionsBaseline urine cultureOral antibiotic optionsEmergent adverse eventsUrinary tract infectionMultidrug-resistant infectionsAdult womenTreatment of adult womenAmoxicillin/clavulanate groupDouble-dummyActive controlled trialAntibiotic optionsUrine cultureOral antibioticsResistant uropathogensDouble-blindStudy drugPrimary endpointP-1106. Sulopenem is Efficacious in a Rabbit Model of Inhalational Anthrax
Puttagunta S, Aronin S, Halasohoris S, Babyak A, Spencer J, Gray A, Torres M, Klimko C, Cote C, Hourihan M, Meinig J. P-1106. Sulopenem is Efficacious in a Rabbit Model of Inhalational Anthrax. Open Forum Infectious Diseases 2025, 12: ofae631.1294. PMCID: PMC11778110, DOI: 10.1093/ofid/ofae631.1294.Peer-Reviewed Original ResearchPost-exposure prophylaxisInhalational anthraxRabbit model of inhalational anthraxResistance to 3rd generation cephalosporinsMedical countermeasuresRabbit modelCDC tier 1 select agentHuman equivalent dosePositive efficacy resultsB-lactam antibioticsSaline control groupTier-1 select agentStandard of careFemale New Zealand White rabbitsResistant bacterial infectionsNew Zealand white rabbitsRisk of antibiotic resistanceDevelopment of novel medical countermeasuresTreatment of resistant bacterial infectionsIn vitro activityEncoding ESBLCiprofloxacin groupEnterobacterales speciesZealand white rabbitsGeneration cephalosporins
2024
A phase 3 randomized trial of sulopenem vs. ertapenem in patients with complicated intra-abdominal infections
Dunne M, Aronin S, Das A, Akinapelli K, Breen J, Zelasky M, Puttagunta S. A phase 3 randomized trial of sulopenem vs. ertapenem in patients with complicated intra-abdominal infections. Clinical Microbiology And Infection 2024, 31: 396-401. PMID: 39491784, DOI: 10.1016/j.cmi.2024.10.025.Peer-Reviewed Original ResearchComplicated intraabdominal infectionsIntraabdominal infectionsPhase 3 randomized trialErtapenem-treated patientsClinical success rateRandomized to 5Confidence intervalsNon-inferiority marginOral regimensAmoxicillin-clavulanateClinical responsePrimary endpointTreatment armsIsolated pathogensTreatment durationHospitalized adultsErtapenemB. fragilisPatientsSuccess rateSulopenemInfectionEndpointTreatment differencesDays
2023
2106. Desirability of Outcome Ranking (DOOR): Application to a Phase 3 Registrational Trial Evaluating Sulopenem for Patients with Complicated Intra-abdominal Infection (cIAI)
Aronin S, Dunne M, Gupta J, Puttagunta S. 2106. Desirability of Outcome Ranking (DOOR): Application to a Phase 3 Registrational Trial Evaluating Sulopenem for Patients with Complicated Intra-abdominal Infection (cIAI). Open Forum Infectious Diseases 2023, 10: ofad500.1730. PMCID: PMC10678622, DOI: 10.1093/ofid/ofad500.1730.Peer-Reviewed Original Research2568. Characterization of Sulopenem Pharmacokinetics-Pharmacodynamics Using a One-Compartment In Vitro Infection Model
VanScoy B, Jones S, Conde H, Vincent C, Bhavnani S, Rubino C, Aronin S, Puttagunta S, Ambrose P. 2568. Characterization of Sulopenem Pharmacokinetics-Pharmacodynamics Using a One-Compartment In Vitro Infection Model. Open Forum Infectious Diseases 2023, 10: ofad500.2185. PMCID: PMC10678615, DOI: 10.1093/ofid/ofad500.2185.Peer-Reviewed Original ResearchUncomplicated urinary tract infectionsDose-ranging studyVitro infection modelMedical CenterMIC ratioInfection modelNet bacterial stasisUrinary tract infectionPK-PD indexDose fractionation studiesPlasma concentration-time profilesOral drug administrationGrant/research supportOne-compartmentTotal daily exposureConcentration-time profilesDrug-resistant pathogensTract infectionsMIC targetsOral prodrugOrganic anion transport inhibitorBacterial burdenMIC valuesRenal excretionDose selection2569. Pharmacokinetic-Pharmacodynamic Evaluation of Sulopenem Using a Five-Day Hollow-Fiber In Vitro Infection Model
VanScoy B, Conde H, Vincent C, Bhavnani S, Aronin S, Puttagunta S, Ambrose P. 2569. Pharmacokinetic-Pharmacodynamic Evaluation of Sulopenem Using a Five-Day Hollow-Fiber In Vitro Infection Model. Open Forum Infectious Diseases 2023, 10: ofad500.2186. PMCID: PMC10677872, DOI: 10.1093/ofid/ofad500.2186.Peer-Reviewed Original ResearchVitro infection modelUncomplicated urinary tract infectionsDrug-resistant subpopulationsMedical CenterInfection modelUrine concentrationsDrug resistance amplificationMurine thigh modelUrinary tract infectionEscherichia coli clinical isolatesInitial burdenFree drug plasma concentrationSimulated pharmacokinetic profilesFive-day study periodGrant/research supportConcentration-time profilesPO q12hTract infectionsOral prodrugOrganic anion transport inhibitorBacterial burdenControl regimenPharmacodynamic evaluationRenal excretionPlasma concentrations